These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16550753)

  • 1. Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy.
    Wen YK; Chen ML
    Clin Nephrol; 2006 Mar; 65(3):211-5. PubMed ID: 16550753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis.
    Viganò M; Colombo M; Aroldi A; Lunghi G; Manenti E; Ponticelli C; Lampertico P
    Antivir Ther; 2005; 10(6):709-13. PubMed ID: 16218169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is lamivudine a safe and effective therapy for patients with chronic hepatitis B and advanced liver disease?
    Karayiannis P; Thomas HC
    Nat Clin Pract Gastroenterol Hepatol; 2005 Mar; 2(3):138-9. PubMed ID: 16265154
    [No Abstract]   [Full Text] [Related]  

  • 5. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.
    Villeneuve JP; Condreay LD; Willems B; Pomier-Layrargues G; Fenyves D; Bilodeau M; Leduc R; Peltekian K; Wong F; Margulies M; Heathcote EJ
    Hepatology; 2000 Jan; 31(1):207-10. PubMed ID: 10613747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
    Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N
    Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamivudine for nephrotic syndrome related to hepatitis B virus (HBV) infection.
    Kanaan N; Horsmans Y; Goffin E
    Clin Nephrol; 2006 Mar; 65(3):208-10. PubMed ID: 16550752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
    Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
    J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term (7-year-) treatment with lamivudine monotherapy in HBV-associated glomerulonephritis.
    Mesquita M; Lasser L; Langlet P
    Clin Nephrol; 2008 Jul; 70(1):69-71. PubMed ID: 18793553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.
    Sponseller CA; Bacon BR; Di Bisceglie AM
    Liver Transpl; 2000 Nov; 6(6):715-20. PubMed ID: 11084057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological outcome during long-term lamivudine therapy.
    Dienstag JL; Goldin RD; Heathcote EJ; Hann HW; Woessner M; Stephenson SL; Gardner S; Gray DF; Schiff ER
    Gastroenterology; 2003 Jan; 124(1):105-17. PubMed ID: 12512035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Polyarteritis nodosa and hepatitis B infection treated with lamivudine].
    Münster T; Weis NM; Krogsgaard K
    Ugeskr Laeger; 2002 Jan; 164(3):342-3. PubMed ID: 11816334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
    Chan HL; Wong VW; Tse AM; Tse CH; Chim AM; Chan HY; Wong GL; Sung JJ
    Clin Gastroenterol Hepatol; 2007 Dec; 5(12):1462-8. PubMed ID: 18054753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Lamivudine treatment of patients with decompensated HBV cirrhosis and mutation in YMDD motif].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):77-8. PubMed ID: 15670511
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful entecavir plus prednisolone treatment for hepatitis B virus-associated membranoproliferative glomerulonephritis: A case report.
    Kataoka H; Mochizuki T; Akihisa T; Kawasoe K; Kawachi K; Makabe S; Sawada A; Manabe S; Sato M; Amemiya N; Mitobe M; Akanuma T; Ito Y; Inoue T; Suzuki T; Matsui K; Moriyama T; Horita S; Ohara M; Honda K; Nitta K
    Medicine (Baltimore); 2019 Jan; 98(2):e14014. PubMed ID: 30633192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term lamivudine therapy in patients with chronic hepatitis B.
    Chien RN; Liaw YF
    Intervirology; 2003; 46(6):362-6. PubMed ID: 14688453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine.
    Manolakopoulos S; Bethanis S; Koutsounas S; Goulis J; Vlachogiannakos J; Christias E; Saveriadis A; Pavlidis C; Triantos C; Christidou A; Papatheodoridis G; Karamanolis D; Tzourmakliotis D
    Aliment Pharmacol Ther; 2008 Feb; 27(3):266-73. PubMed ID: 17988233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B.
    Tsubota A; Arase Y; Suzuki Y; Suzuki F; Sezaki H; Hosaka T; Akuta N; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    J Gastroenterol Hepatol; 2005 Mar; 20(3):426-32. PubMed ID: 15740488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durability of serologic response after lamivudine treatment of chronic hepatitis B.
    Dienstag JL; Cianciara J; Karayalcin S; Kowdley KV; Willems B; Plisek S; Woessner M; Gardner S; Schiff E
    Hepatology; 2003 Apr; 37(4):748-55. PubMed ID: 12668966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.